Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 69Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 21Hodgkin Disease 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

tremelimumab 4Ipilimumab 4lenvatinib 3durvalumab 3Nivolumab 3pembrolizumab 2balstilimab 2Pemetrexed 2Carboplatin 2Bevacizumab 2spartalizumab 1relatlimab 1poly ICLC 1osimertinib 1cemiplimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Platinum 1Peptides 1Paclitaxel 1Opdualag 1Docetaxel 1Capecitabine 1Blood Specimen Collection 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Nivolumab × 1 year × Clear all
NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

Biocon Limited

Phase 1 Not yet recruiting
120 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

AstraZeneca

Phase 3 Active not recruiting
1,116 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

University of Pittsburgh

Phase 2 Completed
20 enrolled 13 charts
Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡